Option chain shows key data for Heineken's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Heineken.

Heineken (OTC:HEINY) Stock, Option Chain

Heineken

Heineken sold 243 million hectoliters of beer in 2023, and is the world's second-largest brewer behind Anheuser-Busch InBev. It has the leading position in many European markets, including the Netherlands, Austria, Greece, and Italy. Its flagship brand, Heineken, is the world's leading international premium lager by volume and has spawned several brand extensions including Heineken 0.0 and Heineken Silver. Heineken is the world's biggest cider producer, and its portfolio also includes brands in the nonalcoholic, Belgian, and craft beer categories.

Tariffs,Increasing,Concept,With,Red,Graph,In,The,Backdrop,Of

Politics

Global

Movers

Trading Ideas

ETFs

AAPL

CVGW

DLTR

HEINY

LMNR

LULU

MCHI

ODFL

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Donald Trump placing tariffs on Canada, China and Mexico could impact multiple sectors. A look at the areas where Americans could see higher prices soon.

Why Beer, Tequila, Avocados, Cars, iPhone Prices Could Rise: Trump&#39;s Tariffs On Canada, Mexico, China To Hurt Several Sectors

Corona,Extra,Beer,Bottles,On,Shelves,In,A,Supermarket.,Buyer

Beers imported from Mexico could become more expensive under Donald Trump&#39;s tariff plan, which could be bad news for fans of Modelo and Corona.

Trump Tariffs On Mexico Could Affect Beer: Why Your Modelo, Corona Could Cost More Next Year

Dogecoin.executium-r9dG85a7E_U-unsplash

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

ADDYY

NDAQ

RBLX

VWAGY

Meme cryptocurrency Dogecoin (CRYPTO: DOGE) is soaring in price and valuation, up more than 80% in the past week and setting new 52-week highs.

Much Wow! Dogecoin Is Now Larger Than Ford, Adidas, Lululemon, Roblox: 15 Companies Worth Less Than Meme Crypto

Heineken NV

News

Guidance

PZZA

Papa John's Sees FY25 System-Wide Sales Up 2%-5%, Sees FY25 Adjusted EBITDA $200M-$220M, Sees FY25 North America Gross Restaurant Openings 85-115, International 180-200

<p>JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $2.37 by 10.13 percent. This is a 5.24 percent increase over earnings of $2.48 per share from the same period last year.  The company reported quarterly sales of $2.19 billion which missed the analyst consensus estimate of $2.22 billion by 1.53 percent.  This is a 1.93 percent decrease over sales of $2.23 billion the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

JM Smucker Q3 Adj $2.61 Beats $2.37 Estimate, Sales $2.19B Miss $2.22B Estimate

NXST

Nextar Media Sees FY25 Adj. EBITDA $1.5B-$1.595B

<p>AAON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.54 by 44.44 percent. This is a 46.43 percent decrease over earnings of $0.56 per share from the same period last year.  The company reported quarterly sales of $297.72 million which missed the analyst consensus estimate of $320.49 million by 7.11 percent.  This is a 2.82 percent decrease over sales of $306.37 million the same period last year.</p>


AAON

AAON Q4 2024 GAAP EPS $0.30 Misses $0.54 Estimate, Sales $297.72M Miss $320.49M Estimate

<p>Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) reported quarterly earnings of $3.33 per share which beat the analyst consensus estimate of $3.31 by 0.6 percent. This is a 7.76 percent decrease over earnings of $3.61 per share from the same period last year.  The company reported quarterly sales of $53.31 million which beat the analyst consensus estimate of $52.05 million by 2.42 percent.  This is a 8.66 percent increase over sales of $49.06 million the same period last year.</p>


ESEA

Euroseas Q4 Adj EPS $3.33 Beats $3.31 Estimate, Sales $53.31M Beat $52.05M Estimate

PENN

PENN Entertainment Q4 2024 Adj. EPS $(0.44) Misses $(0.38) Estimate, Sales $1.669B Miss $1.681B Estimate

<p>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.08 by 75 percent.  The company reported quarterly sales of $90.55 million which missed the analyst consensus estimate of $93.82 million by 3.49 percent.  This is a 22.98 percent decrease over sales of $117.55 million the same period last year.</p>


IRWD

Ironwood Pharmaceuticals Q4 2024 Adj EPS $0.02 Misses $0.08 Estimate, Sales $90.55M Miss $93.82M Estimate

<p>Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.19 by 6.72 percent. This is a 7.97 percent decrease over earnings of $1.38 per share from the same period last year.  The company reported quarterly sales of $42.81 million which beat the analyst consensus estimate of $39.02 million by 9.71 percent.  This is a 52.35 percent increase over sales of $28.10 million the same period last year.</p>


LGND

Ligand Pharmaceuticals Q4 2024 Adj EPS $1.27 Beats $1.19 Estimate, Sales $42.81M Beat $39.02M Estimate

<p>Nexstar Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) reported quarterly earnings of $7.56 per share which missed the analyst consensus estimate of $8.04 by 5.97 percent. This is a 127.71 percent increase over earnings of $3.32 per share from the same period last year.  The company reported quarterly sales of $1.49 billion which met the analyst consensus estimate.  This is a 14.26 percent increase over sales of $1.30 billion the same period last year.</p>


Nexstar Media Gr Q4 2024 GAAP EPS $7.56 Misses $8.04 Estimate, Sales $1.49B Inline

<p>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.34) by 79.41 percent. This is a 35.56 percent decrease over losses of $(0.45) per share from the same period last year.  The company reported quarterly sales of $161.27 million which beat the analyst consensus estimate of $157.81 million by 2.19 percent.  This is a 20.54 percent increase over sales of $133.78 million the same period last year.</p>


NVCR

NovoCure Q4 2024 GAAP EPS $(0.61) Misses $(0.34) Estimate, Sales $161.27M Beat $157.81M Estimate

<p>Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.02 by 50 percent. This is a 200 percent increase over earnings of $0.01 per share from the same period last year.  The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.15 billion by 3.82 percent.  This is a 5.57 percent increase over sales of $1.13 billion the same period last year.</p>


AMBP

Ardagh Metal Packaging Q4 Adj EPS $0.03 Beats $0.02 Estimate, Sales $1.20B Beat $1.15B Estimate

<p>Tecnoglass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGLS#NYSE">TGLS</a>) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $1.02 by 2.94 percent. This is a 31.25 percent increase over earnings of $0.80 per share from the same period last year.  The company reported quarterly sales of $239.57 million which beat the analyst consensus estimate of $239.40 million by 0.07 percent.  This is a 23.11 percent increase over sales of $194.60 million the same period last year.</p>


TGLS

Tecnoglass Q4 2024 Adj EPS $1.05 Beats $1.02 Estimate, Sales $239.57M Beat $239.40M Estimate

<p>In the last three months, 8 analysts have published ratings on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $106.75, a high estimate of $202.00, and a low estimate of $75.00. A 0.59% drop is evident in the current average compared to the previous average price target of $107.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740657652_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Sarepta Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Sarepta Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sarepta Therapeutics analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Sarepta Therapeutics</h2>
<p>Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.</p>
<h3>Unraveling the Financial Story of Sarepta Therapeutics</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Sarepta Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>40.79%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Sarepta Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>7.19%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sarepta Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>2.93%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.96%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.14</strong>, Sarepta Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

SRPT

8 Analysts Have This To Say About Sarepta Therapeutics

Papa John's International Q4 2024 Adj. EPS $0.63 Beats $0.50 Estimate, Sales $530.770M Beat $515.994M Estimate

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $99.75, a high estimate of $110.00, and a low estimate of $89.00. This current average represents a 2.68% decrease from the previous average price target of $102.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740657644_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Best Buy Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Best Buy Co's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Best Buy Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BBY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Best Buy Co analyst ratings.</strong></a></p>
<h2>Get to Know Best Buy Co Better</h2>
<p>With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.</p>
<h3>Best Buy Co: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Best Buy Co faced challenges, resulting in a decline of approximately <strong>-3.19%</strong> in revenue growth as of 31 October, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.89%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Best Buy Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.82%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Best Buy Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.67%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.32</strong>, caution is advised due to increased financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Best Buy Co's Future

<p>During the last three months, 11 analysts shared their evaluations of Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $49.45, a high estimate of $111.00, and a low estimate of $15.00. This current average represents a 32.34% decrease from the previous average price target of $73.09. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740657637_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Keros Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andreas Argyrides</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$41.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Andreas Argyrides</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andreas Argyrides</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$44.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$96.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keros Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Keros Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Keros Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Keros Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KROS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Keros Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Keros Therapeutics</h2>
<p>Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.</p>
<h3>Keros Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Keros Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>4750.0%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Keros Therapeutics's net margin excels beyond industry benchmarks, reaching <strong>-13648.45%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-11.1%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Keros Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-10.24%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Keros Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.04</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


KROS

Analyst Expectations For Keros Therapeutics's Future

<p>In the preceding three months, 4 analysts have released ratings for Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.25, a high estimate of $100.00, and a low estimate of $35.00. Highlighting a 12.34% decrease, the current average has fallen from the previous average price target of $79.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740657629_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Immunocore Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Andrew Galler</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Immunocore Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Immunocore Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Immunocore Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Immunocore Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IMCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Immunocore Hldgs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into Immunocore Hldgs's Background</h2>
<p>Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.</p>
<h3>Immunocore Hldgs's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Immunocore Hldgs's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>23.74%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Immunocore Hldgs's net margin excels beyond industry benchmarks, reaching <strong>10.89%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.37%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Immunocore Hldgs's ROA excels beyond industry benchmarks, reaching <strong>0.83%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Immunocore Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.27</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IMCR

What Analysts Are Saying About Immunocore Hldgs Stock

<p>8 analysts have expressed a variety of opinions on Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $46.62, a high estimate of $50.00, and a low estimate of $40.00. This current average represents a 8.59% decrease from the previous average price target of $51.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740657620_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Freeport-McMoRan. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$40.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Bob Brackett</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$46.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Freeport-McMoRan. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Freeport-McMoRan compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Freeport-McMoRan's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Freeport-McMoRan's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FCX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Freeport-McMoRan analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Freeport-McMoRan</h2>
<p>Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at end December 2024. we expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.</p>
<h3>Freeport-McMoRan: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Freeport-McMoRan's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-3.13%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Freeport-McMoRan's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>4.79%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.56%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.5%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Freeport-McMoRan's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.55</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Freeport-McMoRan Stock

<p>Clear Secure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.5, along with a high estimate of $45.00 and a low estimate of $42.00. The current average, unchanged from the previous average price target, holds steady. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740657612_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Clear Secure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clear Secure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clear Secure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Clear Secure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Clear Secure's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/YOU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Clear Secure analyst ratings.</strong></a></p>
<h2>Discovering Clear Secure: A Closer Look</h2>
<p>Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.</p>
<h3>Unraveling the Financial Story of Clear Secure</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Clear Secure showcased positive performance, achieving a revenue growth rate of <strong>23.72%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>11.83%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Clear Secure's ROE excels beyond industry benchmarks, reaching <strong>16.61%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Clear Secure's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.55%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Clear Secure's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.95</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Clear Secure: 4 Analysts Share Their Views

<p>HC Wainwright &amp; Co.  analyst Raghuram Selvaraju   reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.</p>


Price Target

Reiteration

MLTX

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Press Releases

General

Heineken® Celebrates Historic Irish Pubs With Virtual Museums Launch

Heineken® shows the depth it will go to deliver the perfect pint with giant spirit level measuring bars across the world

Dialing Up Nights Out: Heineken® & Bodega Launch the No-Frills 'Boring Phone'

Heineken Silver is on a mission to end bitterness, starting with one of the biggest love-hate relationships in Marvel Studios' "Deadpool & Wolverine"

Sports

Heineken® Celebrates Thousands of 'Real Hardcore Fans' by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever

Comments

Heineken

Heineken (HEINY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga